ADC Therapeutics (ADCT), a Lausanne, Switzerland-based oncology drug discovery and development company, raised $200m in funding.
The round was led by both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and AstraZeneca.
The company intends to use the proceeds to progress ADCT-301 and ADCT-402 into planned registrational trials in 2018.
ADC Therapeutics specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers.
Its two candidates are currently in four clinical studies in important sub-types of lymphoma and leukemia. The company will also advance ADCT-301 into a combination study for solid tumors and will continue the development of the Phase I study of ADCT-502 in patients with advanced solid tumors with HER2 expression, to file INDs for ADCT-602 and ADCT-601, and to progress a pipeline of pre-clinical ADC programs.
ADCT expects to have a total of eight programs in clinical development within 18 months.